Patent number: 10392413
Abstract: The invention relates to non-systemic TGR5 agonist useful in the treatment of chemotherapy-induced diarrhea, diabetes, Type II diabetes, gestational diabetes, impaired fasting glucose, impaired glucose tolerance, insulin resistance, hyperglycemia, obesity, metabolic syndrome, ulcerative colitis, Crohn's disease, disorders associated with parenteral nutrition especially during short bowel syndrome, and irritable bowel syndrome (IBS), and other TGR5 associated diseases and disorders, having the Formula: where R1, R2, R2?, R3, R4, X1, X2, X3, X4, Q, and n are described herein.
Type:
Grant
Filed:
December 19, 2016
Date of Patent:
August 27, 2019
Assignee:
ARDELYX, INC.
Inventors:
Jason Gustaf Lewis, Michael Robert Leadbetter, Jeremy Caldwell, Dean Dragoli, Noah Bell, Jeffrey W. Jacobs, Patricia Finn, Rakesh Jain, Tao Chen, Matthew Siegel